Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access ...

Data drives decision-making at Aulos Bioscience. It's also driven the career trajectory of its CEO. On this week's episode of the Business of Biotech podcast, we get an introspective walk through Aron ...

Dr. Tal Zaks joins the Business of Biotech for the second part of "Story Time With Tal," discussing his transition from Moderna's CMO during the COVID-19 pandemic to co-founding Exsilio Therapeutics, ...

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski explain the importance of transparency and collaboration when encountering manufacturing speed bumps.

Biopharma guru Allan Shaw speculates on the risks and benefits that the incoming Trump administration could bring to the industry.

Foresite Labs' Vik Bajaj, Ph.D. shares how massive data sets are essential to shortening drug development timelines and creating innovative therapeutics.

Woody Bryan, Ph.D. has founded several biotech companies during his career, and he explains how his journey from scientist to business development prepared him for the C-suite.

Jerry McLaughlin explains the vetting process he used to select Forge Biologics as a CDMO partner.

Foresite Labs' Vik Bajaj, Ph.D. explains how the intersection of science and technology led to the creation of Xiara Therapeutics, which has received $1B in funding.

The upcoming Republican administration promises to shake up the pharmaceutical industry, but Allan Shaw remains optimistic.

Revolo’s plans for 2025 include expanding clinical trials for its lead eosinophilic esophagitis candidate and developing a sublingual delivery method.